L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action
dc.contributor.author | Rose, Christopher | |
dc.contributor.author | Michalak, Adrianna | |
dc.contributor.author | Pannunzio, Pierre | |
dc.contributor.author | Therrien, Guy | |
dc.contributor.author | Quack, Guenter | |
dc.contributor.author | Kircheis, Gerald | |
dc.contributor.author | Butterworth, Roger | |
dc.date.accessioned | 2013-04-23T21:06:10Z | |
dc.date.available | 2013-04-23T21:06:10Z | |
dc.date.issued | 1998-06 | |
dc.identifier.uri | http://hdl.handle.net/1866/9581 | |
dc.subject | Ammonia | en |
dc.subject | Ammoniac | en |
dc.subject | Encéphalopathie hépatique | en |
dc.subject | Glutamine synthesis | en |
dc.subject | Hepatic Encephalopathy | en |
dc.subject | L-Aspartate de L-ornithine | en |
dc.subject | L-ornithine-L-aspartate | en |
dc.subject | Portal-systemic Encephalopathy | en |
dc.title | L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action | |
dc.type | Article | en |
dc.contributor.affiliation | Université de Montréal. Faculté de médecine | fr |
dc.contributor.affiliation | Université de Montréal. Faculté de médecine. Centre de recherche du CHUM | fr |
dc.identifier.doi | 10.1023/A:1020613314572 | |
dcterms.abstract | Strategies aimed at the lowering of blood ammonia remain the treatment of choice in portal-systemic encephalopathy (PSE). L-ornithine-L-aspartate (OA) has recently been shown to be effective in the prevention of ammonia-precipitated coma in humans with PSE. These findings prompted the study of mechanisms of the protective effect of OA in portacaval-shunted rats in which reversible coma was precipitated by ammonium acetate administration (3.85 mmol/kg i.p.). OA infusions (300 mg/kg/h, i.v) offered complete protection in 12/12 animals compared to 0/12 saline-infused controls. This protective effect was accompanied by significant reductions of blood ammonia, concomitant increases of urea production and significant increases in blood and cerebrospinal fluid (CSF) glutamate and glutamine. Increased CSF concentrations of leucine and alanine also accompanied the protective effect of OA. These findings demonstrate the therapeutic efficacy of OA in the prevention of ammonia-precipitated coma in portacaval-shunted rats and suggest that this protective effect is both peripherally-mediated (increased urea and glutamine synthesis) and centrally-mediated (increased glutamine synthesis). | en |
dcterms.language | eng | en |
UdeM.VersionRioxx | Version acceptée / Accepted Manuscript | |
oaire.citationTitle | Metabolic brain disease | |
oaire.citationVolume | 13 | |
oaire.citationIssue | 2 | |
oaire.citationStartPage | 147 | |
oaire.citationEndPage | 157 |
Files in this item
This item appears in the following Collection(s)
This document disseminated on Papyrus is the exclusive property of the copyright holders and is protected by the Copyright Act (R.S.C. 1985, c. C-42). It may be used for fair dealing and non-commercial purposes, for private study or research, criticism and review as provided by law. For any other use, written authorization from the copyright holders is required.